[go: up one dir, main page]

WO2008140483A3 - Methods and antibodies for detecting protective antigen - Google Patents

Methods and antibodies for detecting protective antigen Download PDF

Info

Publication number
WO2008140483A3
WO2008140483A3 PCT/US2007/023624 US2007023624W WO2008140483A3 WO 2008140483 A3 WO2008140483 A3 WO 2008140483A3 US 2007023624 W US2007023624 W US 2007023624W WO 2008140483 A3 WO2008140483 A3 WO 2008140483A3
Authority
WO
WIPO (PCT)
Prior art keywords
protective antigen
antibodies
detecting
anthrax
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/023624
Other languages
French (fr)
Other versions
WO2008140483A2 (en
Inventor
Thi-Sau Migone
Christopher D Ward
Theodore H Hewit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of WO2008140483A2 publication Critical patent/WO2008140483A2/en
Publication of WO2008140483A3 publication Critical patent/WO2008140483A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/32—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The present invention relates to an electrochemiluminescence (ECL) method for detecting the protective antigen of anthrax toxins using antibodies or fragments, or variants thereof, or related molecules that specifically bind to the protective antigen (PA) of Bacillus anthracis (Anthrax). Such ECL detection methods have uses, for example, in detecting protective antigen in sample from an animal, preferably a mammal and most preferably a human and thereby permitting administration of postexposure prophylaxis and/or postexposure small molecule- and protein based therapeutics for treating anthrax exposure.
PCT/US2007/023624 2006-11-09 2007-11-09 Methods and antibodies for detecting protective antigen Ceased WO2008140483A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86514106P 2006-11-09 2006-11-09
US60/865,141 2006-11-09

Publications (2)

Publication Number Publication Date
WO2008140483A2 WO2008140483A2 (en) 2008-11-20
WO2008140483A3 true WO2008140483A3 (en) 2009-04-23

Family

ID=40002783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023624 Ceased WO2008140483A2 (en) 2006-11-09 2007-11-09 Methods and antibodies for detecting protective antigen

Country Status (1)

Country Link
WO (1) WO2008140483A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7173965B2 (en) 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for quantifying unbound C5a in samples
JP7096240B2 (en) * 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド Method for Quantifying Unbound C5 in Sample
CN106554418B (en) * 2016-10-21 2020-06-23 中国人民解放军第三军医大学第一附属医院 Anthrax toxin receptor 2 monoclonal antibody and preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059937A1 (en) * 2000-06-16 2003-03-27 Ruben Steven M. Antibodies that immunospecifically bind BLyS
US20050085740A1 (en) * 2003-04-01 2005-04-21 Davis Cristina E. Non-invasive breath analysis using field asymmetric ion mobility spectrometry
US20050267294A1 (en) * 2002-07-15 2005-12-01 Harvey Barrett R Antibodies with increased affinities for anthrax antigens
US20060218010A1 (en) * 2004-10-18 2006-09-28 Bioveris Corporation Systems and methods for obtaining, storing, processing and utilizing immunologic information of individuals and populations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059937A1 (en) * 2000-06-16 2003-03-27 Ruben Steven M. Antibodies that immunospecifically bind BLyS
US20050267294A1 (en) * 2002-07-15 2005-12-01 Harvey Barrett R Antibodies with increased affinities for anthrax antigens
US20050085740A1 (en) * 2003-04-01 2005-04-21 Davis Cristina E. Non-invasive breath analysis using field asymmetric ion mobility spectrometry
US20060218010A1 (en) * 2004-10-18 2006-09-28 Bioveris Corporation Systems and methods for obtaining, storing, processing and utilizing immunologic information of individuals and populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COTE, C.K. ET AL.: "The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.", MICROBIAL PATHOGENESIS, vol. 38, 22 April 2005 (2005-04-22), pages 209 - 211, 213 *

Also Published As

Publication number Publication date
WO2008140483A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0906903B8 (en) monoclonal antibody and cd70 expression detection method
WO2009029550A3 (en) Highly sensitive system and methods for analysis of prostate specific antigen (psa)
WO2007114947A3 (en) Highly sensitive system and methods for analysis of troponin
WO2005088310A3 (en) High throughput glycan microarrays
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EA200971131A1 (en) BIOMARKERS FOR PREDICTING SENSITIVITY OR NO SENSITIVITY TO ANTI-TNF AGENTS
UA95958C2 (en) Antibody that binds to cd22, immunoconjugates and uses therefor
WO2009137677A3 (en) Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
UA94628C2 (en) Humanized monoclonal antibody that binds to steap-1 and use thereof
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
TW200512457A (en) Method of diagnosing SARS corona virus infection
WO2006099698A3 (en) Novel anti-plgf antibody
MX340547B (en) Diagnostic test kits.
IL213524A0 (en) Method for removing blood group antigens in serum
WO2012010974A3 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
MY157955A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
WO2009139853A3 (en) Human monoclonal antibodies against human chemokine receptor ccr7
WO2009120183A3 (en) System for the detection of a biological pathogen and use thereof
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
BRPI0607350A2 (en) method for detecting the presence or quantity of an erroneously duplicated protein in a sample and kit
WO2008140483A3 (en) Methods and antibodies for detecting protective antigen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874120

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874120

Country of ref document: EP

Kind code of ref document: A2